EMZUMAB 150 Combikit (Omalizumab KIT) 150mg

Emzumab 150 Combikit contains omalizumab 150mg for subcutaneous injection. This kit supports targeted therapy for allergic conditions. Ideal for patients seeking precise allergy management. Store between 2-8°C to maintain potency.

Strength

150mg

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Cipla Ltd.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Emzumab 150 Combikit is used to help control moderate to severe allergic asthma when symptoms persist despite inhaled treatments. It may also be prescribed for chronic urticaria (hives) that does not respond to antihistamines. This medication works by targeting immunoglobulin E (IgE), a key player in allergic reactions. Patients often ask, 'What is omalizumab used for?' when considering this therapy.

Side Effects

After starting Emzumab 150 Combikit, many patients notice a gradual reduction in allergy symptoms such as wheezing, coughing, or skin reactions. Some users report improved breathing comfort and fewer flare-ups over time. Individual responses vary, and effects may take several weeks to become noticeable. Always follow healthcare provider guidance during treatment.

Precautions & Warnings

Keep the Emzumab 150 Combikit refrigerated between 2-8°C and protect it from light. Do not freeze or shake the vial vigorously. Before use, allow the kit to reach room temperature for about 20 minutes. Always check the solution for particles or discoloration. Discard any unused product as directed by your pharmacist.

Avoid Interactions

Emzumab 150 Combikit is a monoclonal antibody and has a low potential for drug interactions. However, live vaccines should be avoided during treatment due to possible reduced immune response. Inform your doctor about all medications, including over-the-counter products. No specific interactions with common allergy or asthma drugs have been widely reported.

Frequently Asked Questions

Effects may appear gradually over several weeks of regular use. Individual response times vary.

Consult your healthcare provider before using this medication if pregnant or planning pregnancy.

Contact your healthcare provider for guidance if a dose is missed. Do not take two doses at once.

No, omalizumab is a monoclonal antibody that targets IgE, not a corticosteroid.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.